Shandong Boan Biotechnology Co., Ltd. (HKG:6955)
Hong Kong · Delayed Price · Currency is HKD 17.60
+0.50 (2.92%)
Last updated: Jul 17, 2025
HKG:6955 Revenue
In the year 2024, Shandong Boan Biotechnology had annual revenue of 726.32M CNY with 17.50% growth. Shandong Boan Biotechnology had revenue of 363.37M in the half year ending December 31, 2024, with 23.06% growth.
Revenue
726.32M CNY
Revenue Growth
+17.50%
P/S Ratio
12.77
Revenue / Employee
955.68K CNY
Employees
760
Market Cap
9.87B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 726.32M | 108.19M | 17.50% |
| Dec 31, 2023 | 618.13M | 102.17M | 19.80% |
| Dec 31, 2022 | 515.96M | 357.26M | 225.11% |
| Dec 31, 2021 | 158.70M | - | - |
| Dec 31, 2020 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines | 32.49B |
| Hansoh Pharmaceutical Group Company | 13.05B |
| Innovent Biologics | 10.03B |
| JD Health International | 61.89B |
| Sino Biopharmaceutical | 30.72B |
| WuXi Biologics | 19.87B |
| Akeso | 2.26B |
| CSPC Pharmaceutical Group | 28.99B |